Free Trial

Humana (HUM) Stock Forecast & Price Target

$385.80
+0.85 (+0.22%)
(As of 07/23/2024 ET)

Humana - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 22 Wall Street analysts who have issued ratings for Humana in the last 12 months, the stock has a consensus rating of "Hold." Out of the 22 analysts, 13 have given a hold rating, and 9 have given a buy rating for HUM.

Consensus Price Target

$402.05
4.21% Upside
High Forecast$579.00
Average Forecast$402.05
Low Forecast$310.00

According to the 22 analysts' twelve-month price targets for Humana, the average price target is $402.05. The highest price target for HUM is $579.00, while the lowest price target for HUM is $310.00. The average price target represents a forecasted upside of 4.21% from the current price of $385.81.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
8 Buy rating(s)
9 Buy rating(s)
12 Buy rating(s)
Hold
13 Hold rating(s)
13 Hold rating(s)
10 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$402.05$410.47$433.74$591.11
Forecasted Upside4.21% Upside13.78% Upside17.20% Upside19.33% Upside
Get Humana Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.

HUM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HUM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Humana Stock vs. The Competition

TypeHumanaMedical CompaniesS&P 500
Consensus Rating Score
2.41
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside4.21% Upside2,973.34% Upside9.72% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/23/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingNeutral ➝ Neutral$360.00 ➝ $360.00-6.58%
7/15/2024Truist Financial
1 of 5 stars
 Boost TargetHold ➝ Hold$355.00 ➝ $400.00+2.66%
6/26/2024Piper Sandler
2 of 5 stars
 Initiated CoverageOverweight$392.00+10.15%
6/24/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageEqual Weight$374.00+5.21%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$374.00+8.31%
5/20/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$342.00 ➝ $376.00+5.56%
4/25/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$415.00 ➝ $353.00+14.10%
4/25/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$334.00 ➝ $326.00+5.43%
4/25/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$415.00 ➝ $370.00+17.07%
4/22/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$411.00 ➝ $381.00+15.74%
4/8/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$413.00 ➝ $350.00+11.78%
4/3/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$450.00 ➝ $385.00+24.47%
4/2/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$356.00 ➝ $310.00+0.93%
4/2/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$427.00 ➝ $396.00+32.04%
3/22/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
3/13/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
1/26/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$550.00 ➝ $400.00+10.46%
1/26/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$550.00 ➝ $430.00+18.45%
1/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$595.00 ➝ $360.00-10.54%
11/17/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$593.00 ➝ $575.00+13.90%
10/10/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$599.00 ➝ $579.00+15.49%
4/27/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$640.00 ➝ $600.00+18.70%
2/6/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$647.00 ➝ $581.00+21.91%
2/6/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$635.00 ➝ $575.00+20.65%
11/7/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$547.00 ➝ $647.00+17.20%
11/3/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$540.00 ➝ $640.00+14.37%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:19 AM ET.

HUM Forecast - Frequently Asked Questions

What is Humana's forecast for 2024?

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Humana is $402.05, with a high forecast of $579.00 and a low forecast of $310.00.

Should I buy or sell Humana stock right now?

22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 13 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HUM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUM, but not buy additional shares or sell existing shares.

Does Humana's stock price have much upside?

According to analysts, Humana's stock has a predicted upside of 11.21% based on their 12-month stock forecasts.

Has Humana been upgraded by Wall Street analysts recently?

Over the previous 90 days, Humana's stock had 1 upgrade by analysts.

What analysts cover Humana?
Do Wall Street analysts like Humana more than its competitors?

Analysts like Humana less than other "medical" companies. The consensus rating for Humana is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HUM compares to other companies.


This page (NYSE:HUM) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners